- Home
- SLS vs CBIO Comparison
SLS vs CBIO Comparison
Compare SLS & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLS
- CBIO
- Stock Information
- Founded
- SLS 2012
- CBIO 2003
- Country
- SLS United States
- CBIO United States
- Employees
- SLS N/A
- CBIO N/A
- Industry
- SLS Biotechnology: Pharmaceutical Preparations
- CBIO
- Sector
- SLS Health Care
- CBIO
- Exchange
- SLS Nasdaq
- CBIO Nasdaq
- Market Cap
- SLS 185.3M
- CBIO 173.5M
- IPO Year
- SLS N/A
- CBIO N/A
- Fundamental
- Price
- SLS $1.69
- CBIO $12.80
- Analyst Decision
- SLS Strong Buy
- CBIO Strong Buy
- Analyst Count
- SLS 1
- CBIO 5
- Target Price
- SLS $7.00
- CBIO $25.60
- AVG Volume (30 Days)
- SLS 2.0M
- CBIO 90.6K
- Earning Date
- SLS 11-12-2025
- CBIO 07-31-2025
- Dividend Yield
- SLS N/A
- CBIO N/A
- EPS Growth
- SLS N/A
- CBIO N/A
- EPS
- SLS N/A
- CBIO N/A
- Revenue
- SLS N/A
- CBIO N/A
- Revenue This Year
- SLS N/A
- CBIO N/A
- Revenue Next Year
- SLS N/A
- CBIO N/A
- P/E Ratio
- SLS N/A
- CBIO N/A
- Revenue Growth
- SLS N/A
- CBIO N/A
- 52 Week Low
- SLS $0.77
- CBIO $10.83
- 52 Week High
- SLS $2.27
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- SLS 42.73
- CBIO 45.54
- Support Level
- SLS $1.65
- CBIO $12.03
- Resistance Level
- SLS $2.01
- CBIO $14.50
- Average True Range (ATR)
- SLS 0.11
- CBIO 0.87
- MACD
- SLS -0.02
- CBIO -0.12
- Stochastic Oscillator
- SLS 11.11
- CBIO 27.11
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.